Sort
21,453 grants matching “tuberculosis”
Structure-based design of antifungal inhibitors targeting the glycosylphosphatidylinositol (GPI) ethanolamine phosphate transferase, Mcd4
$170,000Terry Roemer · Prokaryotics, Inc. · R21 · FY2025 · AI
Small Molecule Alanine Racemase Inhibitors as Novel Therapeutics for Tuberculosis
$169,964Karen G. Anthony · L2 Diagnostics, Llc · R43 · FY2006 · AI
Myocardial Fibrosis and Steatosis Burden and Region-Specific Predictors of Progression among ART-treated Women with HIV infection in sub-Saharan Africa (The MUTIMA Study)
$169,960Chris Todd Longenecker · University Of Washington · R01 · FY2025 · HL
Patient-Oriented Research and Mentoring in Pneumocystis
$169,937Laurence Huang · University Of California, San Francisco · K24 · FY2009 · HL
Patient-Oriented Research and Mentoring in Pneumocystis
$169,936Laurence Huang · University Of California, San Francisco · K24 · FY2010 · HL
Patient-Oriented Research and Mentoring in Pneumocystis
$169,936Laurence Huang · University Of California, San Francisco · K24 · FY2008 · HL
Technology Core: Sequencing
$169,933Thomas R Ioerger · Harvard School Of Public Health · U19 · FY2015 · AI
AI-MedWise: Developing and validating an artificial intelligence solution for effective video-based monitoring of medication adherence
$169,875Juliet Nabbuye Sekandi · University Of Georgia · R21 · FY2025 · LM
Pulmonary impairment after tuberculosis in Georgia: Enhancing clinical research capacity to address the intersection of non-communicablediseases and tuberculosis
$169,818Maia Kipiani · National Center For Tuberculosis And Lung Diseases Jsc(Joint Stock Company) · R21 · FY2020 · TW
An implementation science approach to the design and evaluation of tuberculosis self-testing in Peru
$169,817Yeon Soo Baik · Johns Hopkins University · K01 · FY2023 · HL
Pharmacology Core
$169,750Francesca T. Aweeka · University Of California, San Francisco · P30 · FY2007 · AI
Extended follow-up of randomized participants in the INSIGHT START trial
$169,745James Dennis Neaton · University Of Minnesota · U01 · FY2020 · AI
Data Management and Statistical Support
$169,683Kiat Ruxrungtham · Hiv-Nat, The Thai Red Cross Aids Rch Ctr · U19 · FY2010 · AI
T-regs mediated immune responses in LTBI HIV positive individuals
$169,676Ramakrishna Vankayalapati · University Of Texas Hlth Ctr At Tyler · R21 · FY2016 · AI
DOT Selfie: A Mobile Health Intervention with Transfer of Social Bundle Incentives to Increase Treatment Adherence in Tuberculosis Patients in Uganda
$169,613Juliet Nabbuye Sekandi · University Of Georgia · R21 · FY2019 · TW
Establishing the Value of Treatment Strategies in Spondyloarthritis
$169,560Maureen Dubreuil · Boston University Medical Campus · K23 · FY2020 · AR
Establishing the Value of Treatment Strategies in Spondyloarthritis
$169,560Maureen Dubreuil · Boston University Medical Campus · K23 · FY2016 · AR
Establishing the Value of Treatment Strategies in Spondyloarthritis
$169,560Maureen Dubreuil · Boston University Medical Campus · K23 · FY2017 · AR
Establishing the Value of Treatment Strategies in Spondyloarthritis
$169,560Maureen Dubreuil · Boston University Medical Campus · K23 · FY2019 · AR
NEWLY IDENTIFIED ANTIGENS FOR GAMMA/DELTA T CELLS
$169,500Brigham And Women'S Hospital · R29 · FY2000 · AI
M.tuberculosis Protease ClpP1P2 - An attractive drug target
$169,500Alfred L Goldberg · Harvard Medical School · R21 · FY2011 · NS
Technology Core: Sequencing
$169,486Thomas R Ioerger · Harvard School Of Public Health · U19 · FY2014 · AI
TUBERCULOSIS CONTROL PROGRAM AND AIDS
$169,453Christine G Hahn · Idaho State Dept Of Health And Welfare · U52 · FY2006 · PS
TUBERCULOSIS CONTROL PROGRAM AND AIDS
$169,452Christine G Hahn · Idaho State Dept Of Health And Welfare · U52 · FY2007 · PS
NEW HAMPSHIRE TUBERCULOSIS ELIMINATION AND LABORATORY COOPERATIVE AGREEMENT
$169,436Jose Their Montero · Nh State Dept/Hlth Statistics/Data Mgmt · U52 · FY2015 · PS